Henrik Gregersen

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · The Lancet · 2019 · 636 citations

Medicine, Hematology, Pharmacotherapy +15

Autoimmune and Chronic Inflammatory Disorders and Risk of Non-Hodgkin Lymphoma by Subtype

Karin E. Smedby, Henrik Hjalgrim, Johan Askling et al. · JNCI Journal of the National Cancer Institute · 2006 · 444 citations · Full text

Medicine, Immunology, Autoimmunity +10

Amelioration of some pregnancy-associated variations in thyroid function by iodine supplementation.

Klaus M. Pedersen, Peter Laurberg, Eigil Iversen et al. · The Journal of Clinical Endocrinology & Metabolism · 1993 · 185 citations

Agriculture, Maternal Health, Nutritional Sciences +17

Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial

Ulf‐Henrik Mellqvist, Peter Gimsing, Øyvind Hjertner et al. · Blood · 2013 · 143 citations · Full text

Medicine, Hematology, Oncology +17

UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M‐proteins and the management of monoclonal gammopathy of undetermined significance (MGUS)

Jenny Bird, Judith Behrens, Jan Westin et al. · British Journal of Haematology · 2009 · 137 citations

Medicine, Hematology, Oncology +10